AIM ImmunoTech (AIM) Proxy filing summary

Executive summary

• A special meeting of stockholders is scheduled for July 15, 2026, to vote on seven key proposals, all recommended by the board for approval.

• The proposals focus on authorizing significant issuances of common stock related to warrant exercises and promissory note conversions, as well as a potential reverse stock split.

• The board emphasizes the importance of these approvals for the company's ability to raise capital and maintain operational viability over the next 12 months.

• Failure to approve could result in severe liquidity issues, operational reductions, or bankruptcy risk.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of >19.99% of shares upon exercise of Class H warrants from a May 2026 inducement offer.

• Proposal 2: Approve issuance of >19.99% of shares upon exercise of Class I warrants from a May 2026 securities purchase agreement.

• Proposal 3: Approve issuance of >19.99% of shares upon exercise of Class J warrants from a June 2026 securities purchase agreement.

• Proposal 4: Approve issuance of >19.99% of shares upon conversion of a February 2024 promissory note.

• Proposal 5: Approve issuance of >19.99% of shares upon conversion of a November 2025 promissory note.

• Proposal 6: Approve amendments for a reverse stock split at a ratio up to 1-for-25, at the board's discretion.

• Proposal 7: Approve adjournment of the meeting if more time is needed to solicit votes.

Board of directors and corporate governance

• The board unanimously recommends voting "FOR" all proposals and stresses their necessity for the company's financial health.

• The board retains discretion on the timing and ratio of the reverse stock split, if approved.

• Principal stockholders and directors' beneficial ownership are disclosed, with no director or officer holding a substantial interest in the proposals.